Hsp90 Inhibitor-Evodiamine Conjugates for Colon Cancer Therapy

492.2 KB of structural data for novel antitumor conjugates. The dataset includes results for conjugate 5a, which demonstrated an in vitro antiproliferative IC50 of 7.7 nM and achieved 61.2% tumor growth inhibition via oral administration in vivo. The data was uploaded by Yuhang Sun on figshare in May 2026.

Use Cases

• Structure-activity relationship (SAR) analysis based on the series of rationally designed conjugates
• Evaluating in vivo antitumor efficacy based on reported tumor growth inhibition (TGI) percentages
• Assessing Hsp90 inhibitory activity based on reported IC50 values for conjugate 5a
• Studying endocytosis-mediated drug delivery mechanisms based on the targeting of extracellular Hsp90 (eHsp90)

Strengths

• Includes specific, quantitative bioactivity data (e.g., IC50 = 7.7 nM, TGI = 61.2%)
• Focuses on a rationally designed series of conjugates to address a specific research problem
• Provides in vitro and in vivo efficacy results for a lead compound

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset's 492.2 KB size suggests a limited scope, likely containing only a focused subset of experimental results

Provenance

Source

figshare

Collection Method

Likely contains experimental results from the rational design and testing of Hsp90 inhibitor-evodiamine conjugates.

Freshness

Last updated 2026-05-28 19:45:25; freshness should be verified